SCHEMBL7229226

SCHEMBL7229226

O=C1c2cc(N3CCN(Cc4cccnc4)CC3)ccc2CN1C1CCCCC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.50
PARP2 Q9UGN5 1/20 0.50
KDM4E B2RXH2 3/20 0.48
GFER P55789 1/20 0.48
POLB P06746 1/20 0.47
TSHR P16473 1/20 0.46
MAPK10 P53779 1/20 0.46
TRPV6 Q9H1D0 4/20 0.45
CASP1 P29466 1/20 0.44
CASP4 P49662 1/20 0.44
CASP5 P51878 1/20 0.44
CHRNB2 P17787 1/20 0.44
CHRNA4 P43681 1/20 0.44
CHRM2 P08172 1/20 0.43
CHRM3 P20309 1/20 0.43
KHK P50053 1/20 0.42
HIF1A Q16665 1/20 0.42
EPAS1 Q99814 1/20 0.42
ALDH1A1 P00352 1/20 0.41
TDP1 Q9NUW8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7229644 0.88 DRD4 (0.45) CHRM2CHRM3DRD2DRD4DRD3
SCHEMBL7238561 0.84 MAPT (0.47) KDM4EPOLBTSHRCHRM2CHRM3
SCHEMBL7237830 0.83 MAPT (0.44) KDM4EALDH1A1DRD2DRD4DRD3
SCHEMBL7238118 0.83 CCR5 (0.48) TSHRALDH1A1DRD4
SCHEMBL7230236 0.82 PARP1 (0.46) PARP1PARP2KDM4EALDH1A1
SCHEMBL7230341 0.82 DRD4 (0.44) PARP1PARP2ALDH1A1DRD2DRD4
SCHEMBL7230255 0.82 MAPT (0.46) KDM4EPOLBTSHRALDH1A1DRD2
SCHEMBL7228804 0.81 SMN1; SMN2 (0.45) KDM4EPOLBALDH1A1DRD2DRD4
SCHEMBL7238320 0.81 ADORA2A (0.40) PARP2CASP1CASP4CASP5CHRM3
SCHEMBL7237646 0.80 ALDH1A1 (0.50) KDM4EPOLBTSHRMAPK10KHK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6583144-B2 Piperazine substituted isoquinoline, 1,3-benzoxazine, or 1,3-benzothiazine derivatives; inhibitors against the biosynthesis of triglycerides and secretion of apolipoprotein b and treatment of hyperlipidemia MEIJI SEIKA KAISHA, LTD. (JP) 2003-06-24 US disclosed
US-20020156276-A1 Nitrogen-containing heterocyclic compounds and therapeutic agents for hyperlipidemia comprising the same OHKURA NAOTO (JP) 2002-10-24 US disclosed
US-6417362-B1 PIPERAZINE DERIVATIVES; ARTERIOSCLEROSIS, PANCREATITIS, AND CARDIOVASCULAR DISORDER TREATMENT; SIDE EFFECT REDUCTION MEIJI SEIKA KAISHA, LTD. (JP) 2002-07-09 US disclosed
EP-0999208-A1 NITROGENOUS HETEROCYCLIC COMPOUNDS AND HYPERLIPEMIA REMEDY CONTAINING THE SAME MEIJI SEIKA KAISHA LTD. (JP) 2000-05-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020156276-A1 Nitrogen-containing heterocyclic compounds and therapeutic agents for hyperlipidemia comprising the same APOB, PNLIP, NR1H2 PARP1 4077/4885PARP2 4344/4885KDM4E 3344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.